Navigation Links
AMT Provides Business Update for the Third Quarter 2009
Date:11/18/2009

s with complete and partial lipoprotein lipase deficiency (LPLD).

On October 8, 2009 AMT received Orphan Drug Designation for its treatment for Duchenne Muscular Dystrophy (DMD).

Prospects

The Company remains on track to file for regulatory approval of its lead product Glybera(R) within the next three months. This gene therapy is to control LPLD, a serious disease often complicated by potentially life threatening pancreatitis incidents.

AMT will continue to develop its own technology platform and exploit its advantages in AAV gene therapy by focusing its preclinical development on 4 projects: Hemophilia B, Duchenne Muscular Dystrophy (DMD), Acute Intermittent Porphyria (AIP) and Parkinson's Disease. Other projects previously shown in the Company's pipeline will be postponed or discontinued to control the Company's cash burn.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially diseases that are caused by one faulty gene. Currently, AMT has a pipeline with several AAV-based gene therapy products at different stages of research or development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "go
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. Microbix Biosystems Provides a Corporate Update
5. Alexandria Real Estate Equities, Inc. Provides Update
6. SemBioSys provides an update on Botaneco
7. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
8. New nanostructure technology provides advances in eyeglass, solar energy performance
9. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
11. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Novogen Limited (ASX:NRT; NASDAQ: ... advises that it has entered into definitive agreements ... shares plus one attaching 6-month option and half ... share issued, to institutional investors in ... placement for aggregate gross proceeds of approximately AU$15,500,000 ...
(Date:4/21/2015)... Springfield, Mo. (PRWEB) April 21, 2015 ... vessels, HOLLOWAY AMERICA is slated to discuss its custom ... also present its reimagined website, which launched just prior ... Wed. and Thurs. (April 21, 22 and 23) at ... than 12,000 representatives of the world’s largest and most ...
(Date:4/20/2015)... Winston-Salem, NC and Champaign, IL (PRWEB) April 20, 2015 ... announced today the establishment of its 12th clinical research ... 2015, PMG Research has assumed operation of the clinical ... IL, expanding PMG’s footprint outside the Southeast to a ... site within a 150 multi-specialty physician practice enhances PMG’s ...
(Date:4/20/2015)... -- "Everybody is affected by cancer sooner or later," Dr. ... We,ve got to get away from that."  If you,ve ... loved one or friend battling for their life against ... other treatments cause the human body. It,s almost enough ... succumb to the disease. Dr. Dionne has developed a ...
Breaking Biology Technology:Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... First tenant moves in Stevenage Bioscience Catalyst ... to announce that it is now open for business. In ... , which has taken space in the Incubator building. SBC ... one - discussions with a range of interesting tenants are ...
... Biosciences, a segment of BD (Becton, Dickinson and Company), ... Mesenchymal Stem Cell Serum-Free (hMSC SF), a complete cell ... from bone marrow. The BD Mosaic ... expansion in a shorter culture time—about half the time ...
... 2012  New England Biolabs, Inc. (NEB) and Synthetic Genomics, ... a licensing agreement whereby NEB will introduce a master ... by Dr. Daniel Gibson and his colleagues at the ... program sponsored by SGI. The financial details of this ...
Cached Biology Technology:Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 2Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 3Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 4Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 5Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 6Mesenchymal Stem Cells Have New Cell Culture Environment 2New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications 2New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications 3
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... certified winner of the UC Davis "Western Cooling Challenge" ... that their five-ton commercial rooftop unit should be able ... half the energy needed by conventional cooling units. ... first to take our rigorous tests at the Advanced ...
... Leipzig Max Planck Institute for Human Cognitive and Brain ... London have now developed a mathematical model which could ... language. In the future, this kind of algorithms which ... world around them. Many people will have personal ...
... cells for replication and production of virus progeny. Thus ... induces therapy resistance. New improved therapies attempt to targets ... The team led by Professor Dr. Ralf Bartenschlager, ... Hygiene Institute of Heidelberg University Hospital, has identified a ...
Cached Biology News:UC Davis challenge produces a better air conditioner 2Doing what the brain does -- how computers learn to listen 2Doing what the brain does -- how computers learn to listen 3New strategy for inhibiting virus replication 2
... Blot Processing Standard Tray (3 per ... gel staining and blot processing.Automated staining ... for proteins and nucleic acid analysis.Prepares ... and chromogenic detection.Programmable control of protocol, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
Biology Products: